BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38469839)

  • 21. Patient Perspectives: Propranolol for infantile hemangiomas.
    Pediatr Dermatol; 2016 Sep; 33(5):549-50. PubMed ID: 27595871
    [No Abstract]   [Full Text] [Related]  

  • 22. Low-dose propranolol for infantile hemangioma of the head and neck: Analysis of 23 consecutive patients.
    Ren W; Li S; Gao L; Huang S; Zhang L; Qiang C; Liu C; Zhi K
    Pediatr Int; 2017 Feb; 59(2):213-217. PubMed ID: 27473874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
    Léauté-Labrèze C; Frieden I; Delarue A
    Pediatr Dermatol; 2023 Mar; 40(2):261-264. PubMed ID: 36511888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study.
    Prasad A; Sinha AK; Kumar B; Prasad A; Kumari M
    Pan Afr Med J; 2019; 32():155. PubMed ID: 31303926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outpatient treatment of infantile hemangiomas with propranolol: a prospective study.
    Betlloch-Mas I; Martínez-Miravete MT; Lucas-Costa A; Martin de Lara AI; Selva-Otalaurruchi J
    Actas Dermosifiliogr; 2012 Nov; 103(9):806-15. PubMed ID: 22727954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Color Doppler Evaluation of Arterial Resistive Index in Infantile Hemangioma: A Useful Parameter to Monitor the Response to Oral Propranolol?
    Parapatt GK; Oranges T; Paolantonio G; Ravà L; Giancristoforo S; Diociaiuti A; El Hachem M; Rollo M
    Front Pediatr; 2021; 9():718135. PubMed ID: 34950614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome.
    Schupp CJ; Kleber JB; Günther P; Holland-Cunz S
    Pediatr Dermatol; 2011; 28(6):640-644. PubMed ID: 21995836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas.
    Jacks SK; Kertesz NJ; Witman PM; Fernandez Faith E
    J Am Acad Dermatol; 2015 Aug; 73(2):255-7. PubMed ID: 26054433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial.
    Pope E; Lara-Corrales I; Sibbald C; Liy-Wong C; Kanigsberg N; Drolet B; Ma J
    JAMA Pediatr; 2022 Jan; 176(1):34-41. PubMed ID: 34747977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Propranolol for infantile hemangiomas.
    Bagazgoitia L; Torrelo A; Gutiérrez JC; Hernández-Martín A; Luna P; Gutiérrez M; Baño A; Tamariz A; Larralde M; Alvarez R; Pardo N; Baselga E
    Pediatr Dermatol; 2011; 28(2):108-14. PubMed ID: 21385205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Propranolol Gel for Infantile Hemangioma: A Randomized, Double-Blind Study.
    Rikihisa N; Takatsuka H; Suzuki T; Shiko Y; Kawasaki Y; Hanawa M; Ishii I; Mitsukawa N
    Biol Pharm Bull; 2022 Jan; 45(1):42-50. PubMed ID: 34719577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects.
    Twist J; Chen A; Poffenberger P; Zinn Z
    Pediatr Dermatol; 2022 Mar; 39(2):273-274. PubMed ID: 35178766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population.
    Fu R; Zou Y; Wu Z; Jin P; Cheng J; Bai H; Huang M; Huan X; Yuan H
    Sci Rep; 2023 Apr; 13(1):5956. PubMed ID: 37046020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety assessment of propranolol for infantile hemangioma: a study in an Asian population.
    Yu L; Wei L; Xu Z; Zhang B; Han X; Sun Y; Liu Y; Wang C; Qiu L; Xiu B; He R; Li L; Ma L
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):237-242. PubMed ID: 34918994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth.
    Pam N; Kridin K; Khamaysi Z
    Dermatol Ther; 2021 May; 34(3):e14936. PubMed ID: 33704861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment.
    Lin X; Wang T; Liu C; Deng L; Wang Q; Huang L; Gao J; Chen X; Chen S
    Medicine (Baltimore); 2023 Jun; 102(23):e33998. PubMed ID: 37335657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Propranolol Therapy for Problematic Infantile Hemangioma.
    Ng M; Knuth C; Weisbrod C; Murthy A
    Ann Plast Surg; 2016 Mar; 76(3):306-10. PubMed ID: 26010350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of oral propranolol in the treatment of infantile subglottic hemangioma.
    Li XY; Wang Y; Jin L; Chen JR
    Int J Clin Pharmacol Ther; 2016 Sep; 54(9):675-81. PubMed ID: 27285465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience.
    Georgountzou A; Karavitakis E; Klimentopoulou A; Xaidara A; Kakourou T
    Acta Paediatr; 2012 Oct; 101(10):e469-74. PubMed ID: 22804809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood Pressure Monitoring During the Induction and Maintenance Period of Propranolol Therapy for Complicated Infantile Hemangiomas: A Prospective Study of 109 Infants.
    Hengst M; Oelert M; Hoeger PH
    Pediatr Dermatol; 2015; 32(6):802-7. PubMed ID: 26391729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.